Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVRO NASDAQ:GNFT NYSE:PLX NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsGNFTGENFIT$3.68+0.5%$4.14$2.55▼$6.42$183.01M1.0810,465 shs2,188 shsPLXProtalix BioTherapeutics$1.48+0.7%$1.77$0.82▼$3.10$117.82M-0.23583,850 shs1.01 million shsPROKProKidney$3.73+515.0%$0.82$0.46▼$4.87$177.52M1.262.08 million shs338.88 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO0.00%0.00%0.00%0.00%0.00%GNFTGENFIT-3.51%-1.05%-11.37%+9.70%-11.39%PLXProtalix BioTherapeutics-4.85%-0.68%-6.96%-35.53%+40.00%PROKProKidney-11.97%+2.43%-37.96%+18.71%-73.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBION/AN/AN/AN/AN/AN/AN/AN/AGNFTGENFIT1.5197 of 5 stars3.54.00.00.00.00.00.0PLXProtalix BioTherapeutics2.3151 of 5 stars3.53.00.00.00.00.01.9PROKProKidney0.7447 of 5 stars1.00.00.00.02.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO 0.00N/AN/AN/AGNFTGENFIT 3.00Buy$13.00253.26% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00913.51% UpsidePROKProKidney 2.00Hold$3.50-6.17% DownsideCurrent Analyst Ratings BreakdownLatest AVRO, PROK, GNFT, and PLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/AN/AN/A$2.13 per shareN/AGNFTGENFIT$76.77M2.40$0.07 per share52.33$1.50 per share2.45PLXProtalix BioTherapeutics$59.76M1.97$0.08 per share17.80$0.47 per share3.15PROKProKidney$80K13,647.14N/AN/A($3.41) per share-1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/AGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.04N/A4.77N/A-21.03%-30.89%-11.74%N/APROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)Latest AVRO, PROK, GNFT, and PLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A26.1726.17GNFTGENFIT0.081.231.23PLXProtalix BioTherapeuticsN/A1.981.27PROKProKidneyN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%GNFTGENFIT2.24%PLXProtalix BioTherapeutics16.53%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%GNFTGENFIT4.20%PLXProtalix BioTherapeutics6.50%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.89 million40.76 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableAVRO, PROK, GNFT, and PLX HeadlinesRecent News About These CompaniesStock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz2 hours ago | fool.comProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying3 hours ago | marketwatch.comTop Penny Stocks Worth Watching - July 8th4 hours ago | marketbeat.comBest Small Cap Stocks To Watch Today - July 8th4 hours ago | marketbeat.comProKidney Shares Skyrocket After Favorable Results in Kidney Disease Study5 hours ago | marketwatch.comProKidney Is Soaring on Trial Results. How Should You Play Penny Stock PROK Here?5 hours ago | finance.yahoo.comProKidney (NASDAQ:PROK) Shares Gap Up - Here's WhyJuly 8 at 2:17 PM | marketbeat.comBest Biotech Stocks To Research - July 8thJuly 8 at 12:54 PM | marketbeat.comProKidney Shares Rise on Positive Topline Data in Rilparencel TrialJuly 8 at 11:50 AM | marketwatch.comProKidney’s CKD cell therapy scores win in one half of phase 2 trial, falls short on otherJuly 8 at 11:50 AM | fiercebiotech.comFWhy Is Penny Stock ProKidney Stock Trading Higher On Tuesday?July 8 at 11:50 AM | benzinga.comProKidney spikes after mid-stage trial data for lead assetJuly 8 at 11:50 AM | msn.comProKidney Shares Double on Strong Phase 2 Data for Kidney Disease TherapyJuly 8 at 11:50 AM | msn.comWhy Is Penny Stock ProKidney Trading Higher On Tuesday?July 8 at 10:02 AM | benzinga.comProKidney Corp. Reports Positive Topline Results from Phase 2 REGEN-007 Trial of Rilparencel for Chronic Kidney Disease and Plans Submission to ASN 2025 Kidney WeekJuly 8 at 7:52 AM | quiverquant.comQProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and DiabetesJuly 8 at 7:00 AM | globenewswire.comProKidney Insider Trading Activity | NASDAQ:PROK | BenzingaJuly 4, 2025 | benzinga.comProKidney Corp. Completes Domestication from Cayman Islands to Delaware, Retaining Nasdaq Trading Symbol "PROK"July 3, 2025 | nasdaq.comWinston-Salem's ProKidney shifts incorporation site from Cayman Islands to United StatesJuly 3, 2025 | journalnow.comJProKidney Completes Transition to Delaware IncorporationJuly 1, 2025 | tipranks.comProKidney Corp. Completes Domestication from the Cayman Islands to DelawareJuly 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVRO, PROK, GNFT, and PLX Company DescriptionsAVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.GENFIT NASDAQ:GNFT$3.68 +0.02 (+0.55%) As of 02:59 PM EasternGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Protalix BioTherapeutics NYSE:PLX$1.48 +0.01 (+0.68%) Closing price 04:00 PM EasternExtended Trading$1.48 0.00 (-0.34%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.ProKidney NASDAQ:PROK$3.73 +3.12 (+515.00%) Closing price 04:00 PM EasternExtended Trading$4.05 +0.32 (+8.55%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
